Apellis Pharmaceuticals, Inc.
APLS
$23.33
-$0.16-0.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -228.17M | -223.68M | -197.88M | -250.10M | -332.89M |
| Total Depreciation and Amortization | 1.80M | 1.80M | 1.80M | 1.83M | 1.83M |
| Total Amortization of Deferred Charges | 2.45M | 2.07M | 1.56M | 1.05M | 464.00K |
| Total Other Non-Cash Items | 108.36M | 115.97M | 125.01M | 131.39M | 132.09M |
| Change in Net Operating Assets | 120.06M | 95.54M | -18.36M | -89.26M | -209.77M |
| Cash from Operations | 4.49M | -8.29M | -87.87M | -205.10M | -408.28M |
| Capital Expenditure | -77.00K | -118.00K | -403.00K | -478.00K | -525.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | 99.00K | 99.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -77.00K | -118.00K | -403.00K | -379.00K | -426.00K |
| Total Debt Issued | 0.00 | 365.45M | 365.45M | 365.45M | 365.45M |
| Total Debt Repaid | 1.59M | 1.59M | 1.59M | 1.59M | -- |
| Issuance of Common Stock | 11.04M | 9.63M | 18.83M | 44.28M | 47.48M |
| Repurchase of Common Stock | -36.00K | -36.00K | -57.00K | -44.00K | -41.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7.21M | -335.34M | -236.57M | -261.95M | -260.36M |
| Cash from Financing | 5.37M | 41.30M | 149.24M | 149.33M | 152.53M |
| Foreign Exchange rate Adjustments | 252.00K | -91.00K | -659.00K | 890.00K | 259.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.04M | 32.80M | 60.31M | -55.26M | -255.92M |